Galectin Therapeutics/$GALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Primary listing
Employees
9
Headquarters
Website
GALT Metrics
BasicAdvanced
$149m
-
-$0.48
1.04
-
Price and volume
Market cap
$149m
Beta
1.04
52-week high
$7.13
52-week low
$1.21
Average daily volume
302k
Financial strength
Current ratio
2.42
Quick ratio
2.207
Long term debt to equity
-109.114
Total debt to equity
-109.132
Interest coverage (TTM)
-2.74%
Profitability
Management effectiveness
Return on assets (TTM)
-67.81%
Return on equity (TTM)
26.90%
Valuation
Price to book
-1.15
Price to tangible book (TTM)
-1.15
Price to free cash flow (TTM)
-6.076
Free cash flow yield (TTM)
-16.46%
Free cash flow per share (TTM)
-0.374
Growth
Earnings per share change (TTM)
-36.01%
3-year earnings per share growth (CAGR)
-9.53%
10-year earnings per share growth (CAGR)
-5.74%
What the Analysts think about GALT
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
GALT Financial Performance
Revenues and expenses
GALT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $149M as of May 03, 2026.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of May 03, 2026.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of May 03, 2026.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.